

Long-Acting PrEP Generic Manufacturers

Licenses have been granted to manufacturers across multiple low- and middle-income countries to produce generic long-acting PrEP products. Cabotegravir (CAB) and Lenacapavir (LEN) are approved and rolling out, while alimatravir (AMI) is in Phase 3 efficacy trials. Generic manufacturing can play an important role in expanding access to PrEP, and licensing to three African manufacturers for AMI is a notable step toward strengthening regional supply and affordability.

Manufacturer	Country	 CAB	 LEN	 AMI
 aspen	 South Africa			
 AUROBINDO	 India			
 Cipla	 India			
 Dr.Reddy's	 India			
 Emcure	 India			
 EVA PHARMA	 Egypt			
 FEROZSONS LABORATORIES LIMITED	 Pakistan			
 HETERO	 India			
 Qcil	 Uganda			
 UNIVERSAL CORPORATION LTD	 Kenya			
 VIATRIS	 India			
Total licenses		3	6	7